Patents Issued in January 12, 2021
-
Patent number: 10888560Abstract: The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.Type: GrantFiled: October 1, 2018Date of Patent: January 12, 2021Assignees: The Board of Trustees of the University of Illinois, Vanquish Oncology, Inc.Inventors: Paul J. Hergenrother, Rachel C. Botham, Timothy M. Fan, Mark J. Gilbert, Michael K. Handley, Howard S. Roth, Theodore M. Tarasow
-
Patent number: 10888561Abstract: The disclosures herein relate to novel compounds of formula wherein R1, R2, R3 and R4 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.Type: GrantFiled: April 8, 2019Date of Patent: January 12, 2021Assignee: Heptares Therapeutics LimitedInventors: John Andrew Christopher, Miles Stuart Congreve, Sarah Joanne Bucknell, Francesca Deflorian, Mark Pickworth, Jonathan Stephen Mason
-
Patent number: 10888562Abstract: Tartrate salts of the compound of structure (I), crystalline forms thereof, and therapeutic applications thereof for treating solid tumors (e.g., advanced solid tumor) or hematopoietic cancers. Also provided herein are methods for synthesizing the tartrate salts and the crystalline forms thereof.Type: GrantFiled: April 5, 2019Date of Patent: January 12, 2021Assignee: Sumitomo Dainippon Pharma Oncology, Inc.Inventors: Adam Siddiqui-Jain, Paul Flynn, Akihito Nonoyama, Akihito Kiguchiya
-
Patent number: 10888563Abstract: The invention provides fused heterocyclic organic compounds such as dihydropyrazolopyridotriazinones, compositions containing such compounds, medical kits, and methods for using such compounds and compositions for body contouring and/or reduction of fat in a subject.Type: GrantFiled: July 30, 2018Date of Patent: January 12, 2021Assignee: Alevere Medical CorporationInventor: Tim Kamerzell
-
Patent number: 10888564Abstract: The disclosure generally relates to compounds of formulas (I) and (II)7 including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV-1 integrase, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.Type: GrantFiled: January 26, 2018Date of Patent: January 12, 2021Assignee: Institute for Cancer ResearchInventors: Mark D. Andrake, Anna Marie Skalka, George W. Merkel
-
Patent number: 10888565Abstract: The disclosure relates to compounds and compositions for forming bone and methods related thereto. In one embodiment, the disclosure relates to a composition comprising a compound disclosed herein, such as 2,4-diamino-1,3,5-triazine derivatives or salts thereof, for use in bone growth processes. In a typical embodiment, a bone graft composition is implanted in a subject at a site of desired bone growth or enhancement.Type: GrantFiled: January 2, 2020Date of Patent: January 12, 2021Assignees: Emory University, The United States Government as represented by the Department of Veterans AffairsInventors: Scott D. Boden, Sreedhara Sangadala
-
Patent number: 10888566Abstract: Compounds for the chemosensitization of antibiotic resistant bacteria such as multidrug resistant (MDR) Pseudomonas aeruginosa (Pa) are provided. The compounds inhibit the MDR efflux proteins and re-sensitize the bacteria towards killing by antibiotics. Thus, the compounds are used in combination with antibiotics to treat or prevent infections caused by MDR bacteria.Type: GrantFiled: October 7, 2020Date of Patent: January 12, 2021Assignee: KING ABDULAZIZ UNIVERSITYInventors: Moustafa E. El-Araby, Abdelsattar M. Omar, Mahmoud A. Elfaky, Maan T. Khayat, Ghufran A. Alhowswi, Fatma M. Alhaity, Muna M. Albeeshy
-
Patent number: 10888567Abstract: Pharmaceutical compositions comprising 3-aminoisoxazolopyridine compounds of the Formula I having IDO1 and/or TDO inhibitory activity are described, where W is CR1, N or N-oxide; X is CR2, N or N-oxide; Y is CR3, N or N-oxide; Z is CR4, N or N-oxide; and at least one of W, X, Y, and Z is N or N-oxide; and R9 and R10 are as defined. Also described are methods of using such compounds in the treatment of various conditions, such as cancer.Type: GrantFiled: August 12, 2015Date of Patent: January 12, 2021Assignee: Auckland UniServices LimitedInventors: Brian Desmond Palmer, Lai Ming Ching, Swarnalatha Akuratiya Gamage
-
Patent number: 10888568Abstract: The present invention relates to use of antipsychotic phenothiazine derivative for treatment of cancer. The invention also provides a use for manufacture a medicament, a pharmaceutical composition and a method for treating a cancer, and/or preventing or delaying cancer recurrence based on trifluoperazine. The invention further provides a use for manufacture a medicament, a pharmaceutical composition and a method for treating cancer based on thioridazine and its enantiomers. Additionally, the invention provides a use for manufacture a medicament, a pharmaceutical composition and a method for treating KRAS mutant NSCLC comprising thioridazine.Type: GrantFiled: October 29, 2018Date of Patent: January 12, 2021Assignee: National Yang Ming UniversityInventors: Chi-Ying Huang, Jane Hsiao, Pan-Chyr Yang, Meng-Hua Lee
-
Patent number: 10888569Abstract: The disclosure relates to improved therapeutic methods for treating cancer patients. The methods include a method for treating cancer in a subject comprising administering an effective amount of a BACH1 inhibitor and an ETC inhibitor to the subject. Further aspects of the disclosure relate to a method for treating cancer in a subject comprising: administering a first therapeutic regimen comprising an ETC inhibitor to the subject after a biological sample from the subject was determined to have a decreased or substantially the same level of expression of BACH1 relative to a control sample or to a cut-off value; wherein the first therapeutic regimen excludes a BACH1 inhibitor; or administering a second therapeutic regimen comprising a BACH1 inhibitor and an ETC inhibitor to the subject after a biological sample from the subject was determined to have an increased level of expression of BACH1 relative to a control sample or a cut-off value.Type: GrantFiled: June 11, 2018Date of Patent: January 12, 2021Assignee: The University of ChicagoInventors: Marsha Rosner, Jiyoung Lee
-
Patent number: 10888570Abstract: Disclosed herein is a stable, ready-to-use liquid formulation comprising spironolactone and its method of use.Type: GrantFiled: May 19, 2020Date of Patent: January 12, 2021Assignee: CMP DEVELOPMENT LLCInventors: Anthony Pipho, Michael Paul DeHart
-
Method and composition for increasing muscle protein synthesis and/or functional strength in mammals
Patent number: 10888571Abstract: A method and composition for preserving muscle mass and function by increasing muscle protein synthesis and/or decreasing muscle protein degradation in mammals is disclosed. In one embodiment, the mammals are administered a protein building composition comprising at least two of an essential amino acid, an amino acid derivative, and a nitrogenous organic acid. In a particular embodiment, the protein building composition comprises leucine, L-carnitine, and creatine. The protein building composition can decrease TNF-? and increase mTOR expression in muscle.Type: GrantFiled: December 16, 2016Date of Patent: January 12, 2021Assignee: Lonza Consumer Health Inc.Inventors: Aouatef Bellamine, Ilya Zhivkovich, Ulla Freitas -
Patent number: 10888572Abstract: A hydrated lecithin carrier vesicle composition includes lecithin and a triglyceride source or fatty acid in conditioned water. The disclosed compositions may be used for controlling appetite, weight loss, modulating effects from alcohol consumption, and/or delivering active agents to the small intestine.Type: GrantFiled: December 2, 2016Date of Patent: January 12, 2021Assignee: BIO-UP MIMETIC TECHNOLOGIES, INC.Inventors: Donald F. Hodgson, Crispin G. S. Eley
-
Patent number: 10888573Abstract: Phospholipid preparations effective in improving brain development and brain rehabilitation are provided herein.Type: GrantFiled: March 9, 2017Date of Patent: January 12, 2021Assignee: ENZYMOTEC LTD.Inventors: Asher Widberg, Hala Laoz, Gai Ben-Dror, Yifat Berkov, Yael Lifshitz, Yael Herzog
-
Patent number: 10888574Abstract: The present disclosure relates to a method for suppressing obesity, which includes administering to a subject a compound represented by the following formula wherein n is an integer of 1 to 5; when n is 1, R1 is —OH or —O-glycosyl; when n is an integer of 2 to 5, one R1 is —OH and the other R1(s) is/are —O-glycosyl; and R2 is -glycosyl.Type: GrantFiled: September 28, 2018Date of Patent: January 12, 2021Assignee: KINJIRUSHI CO.. LTD.Inventors: Isao Okunishi, Tomoe Kato
-
Patent number: 10888575Abstract: The invention provides a combination comprising zidovudine or a pharmaceutically acceptable derivative thereof and a carbapenem or a pharmaceutically acceptable derivative thereof, optionally with a polymyxin selected from polymyxin E and polymyxin or a pharmaceutically acceptable derivative thereof. This combination is particularly useful for the treatment of microbial infections.Type: GrantFiled: July 11, 2017Date of Patent: January 12, 2021Inventors: Anthony Coates, Yanmin Hu
-
Patent number: 10888576Abstract: The present invention provides a composition comprising HMB and ATP. Methods of administering HMB and ATP to an animal are also described. HMB and ATP are administered to increase power and strength. The combination of HMB and ATP together has a synergistic effect, which results in a surprising and unexpected level of improvement in power and strength. HMB and ATP are also administered to increase lean body mass and muscle hypertrophy and to prevent typical declines in performance that are characteristic of overreaching.Type: GrantFiled: October 8, 2018Date of Patent: January 12, 2021Assignee: Metabolic Technologies, Inc.Inventors: Shawn Baier, Larry Kolb, John Rathmacher
-
Patent number: 10888577Abstract: There is disclosed herein methods, uses and systems for the detection, diagnosis, prognosis, treatment or prevention of a disease or condition comprising cartilage degeneration in a subject that is in need thereof. The methods comprise the use, inhibition or measurement of at least one of miR-181 a-5p and miR-4454, in the subject.Type: GrantFiled: January 31, 2017Date of Patent: January 12, 2021Assignee: UNIVERSITY HEALTH NETWORKInventors: Mohit Kapoor, Akihiro Nakamura, Raja Rampersaud
-
Patent number: 10888578Abstract: Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 51 skipping are described.Type: GrantFiled: December 13, 2017Date of Patent: January 12, 2021Assignee: Sarepta Therapeutics, Inc.Inventors: Marco A. Passini, Gunnar J. Hanson
-
Patent number: 10888579Abstract: Compositions and methods for reducing susceptibility to infectious disease in bees using RNA interference technology, and more particularly, prevention and treatment of viral infections in honeybees such as Israel acute paralysis virus (IAPV) by feeding of pathogen-specific dsRNA. Further, multiple-pathogen specific dsRNA is disclosed.Type: GrantFiled: July 1, 2013Date of Patent: January 12, 2021Assignee: BEEOLOGICS INC.Inventors: Nitzan Paldi, Gal Yarden
-
Patent number: 10888580Abstract: The present invention provides methods for alleviating pain and discomfort associated with a dry eye condition; methods for alleviating pain and discomfort while minimizing at least one skin imperfection; and methods for alleviating pain and discomfort while facilitating wound healing. The methods involve administering to a subject in need thereof a composition comprising hyaluronan with high elasticity.Type: GrantFiled: July 2, 2019Date of Patent: January 12, 2021Assignee: Matrix Biology InstituteInventors: Carlos Belmonte, Janet L. Denlinger
-
Patent number: 10888581Abstract: The present disclosure provides a heterodimeric, conditionally active chimeric antigen receptor (CAR), and a nucleic acid comprising a nucleotide sequence encoding the CAR. The present disclosure provides cells genetically modified to produce the CAR. A CAR of the present disclosure can be used in various methods, which are also provided.Type: GrantFiled: December 7, 2017Date of Patent: January 12, 2021Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Chia-Yung Wu, James Onuffer, Wendell A. Lim
-
Patent number: 10888582Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: March 10, 2020Date of Patent: January 12, 2021Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Heiko Schuster, Franziska Hoffgaard, Jens Fritsche, Oliver Schoor, Toni Weinschenk, Daniel Johannes Kowalewski, Chih-Chiang Tsou
-
Patent number: 10888583Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: March 27, 2020Date of Patent: January 12, 2021Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Heiko Schuster, Franziska Hoffgaard, Jens Fritsche, Oliver Schoor, Toni Weinschenk, Daniel Johannes Kowalewski, Chih-Chiang Tsou
-
Patent number: 10888584Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: June 12, 2020Date of Patent: January 12, 2021Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Heiko Schuster, Franziska Hoffgaard, Jens Fritsche, Oliver Schoor, Toni Weinschenk, Daniel Johannes Kowalewski, Chih-Chiang Tsou
-
Patent number: 10888585Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: June 12, 2020Date of Patent: January 12, 2021Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Heiko Schuster, Franziska Hoffgaard, Jens Fritsche, Oliver Schoor, Toni Weinschenk, Daniel Johannes Kowalewski, Chih-Chiang Tsou
-
Patent number: 10888586Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: June 12, 2020Date of Patent: January 12, 2021Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Heiko Schuster, Franziska Hoffgaard, Jens Fritsche, Oliver Schoor, Toni Weinschenk, Daniel Johannes Kowalewski, Chih-Chiang Tsou
-
Patent number: 10888587Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: June 18, 2020Date of Patent: January 12, 2021Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Heiko Schuster, Janet Peper, Philipp Wagner, Hans-Georg Rammensee
-
Patent number: 10888588Abstract: Disclosed is a fully chemically defined, small molecule-mediated, directed differentiation system that promotes differentiation of stem cells, including embryonic stem cells, induced pluripotent stem cells, and adult stem cells, such as human forms of these stem cell types, to ventricular cardiomyocytes in a highly efficient, reproducible and scalable fashion. Also disclosed is a cost-effective and efficient protocol, or method, for generating cardiomyocytes and a cost-effective and efficient method of maturing cardiomyocytes. The disclosed differentiation system provides a platform to perform large-scale pharmacological screenings and to provide a valuable source of each of cardiac progenitor cells and cardiomyocytes for cell replacement therapies in cardiac repair.Type: GrantFiled: October 17, 2014Date of Patent: January 12, 2021Assignees: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, THE UNIVERSITY OF HONG KONGInventors: Roger Joseph Hajjar, Camie W. Chan
-
Patent number: 10888589Abstract: Methods and compositions for modifying stem cells using one or more ZFPs are disclosed. Such methods and compositions are useful for facilitating processes such as, for example, dedifferentiating cells, differentiating stem cells into the desired phenotype, propagating stem cells and/or facilitating cloning.Type: GrantFiled: April 13, 2017Date of Patent: January 12, 2021Assignee: Sangamo Therapeutics, Inc.Inventors: Alan P. Wolffe, Michael Moore, Timothy Farries, Trevor Collingwood, Fyodor Urnov
-
Patent number: 10888590Abstract: The present invention is directed to a medicated oil composition comprising propolis, about 1-40% by weight, a carrier, about 30-90% by weight, an analgesic, about 0.1-10% by weight, a surfactant, about 0.25-20% by weight, and a diluent, about 5-50% by weight.Type: GrantFiled: July 23, 2018Date of Patent: January 12, 2021Assignee: MatrixMed Inc.Inventors: Randal Alexander Serafini, Shiv Krishnan, Jonathan Patrick Masterson, IV
-
Patent number: 10888591Abstract: Provided are vesicles derived from bacteria belonging to the genus Micrococcus, a composition and a use thereof, wherein the vesicles and the composition comprising the same may be effectively used for the development of a method of diagnosing gastric cancer, pancreatic cancer, cholangiocarcinoma, breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina, chronic obstructive pulmonary disease (COPD), dementia, or diabetes.Type: GrantFiled: September 6, 2019Date of Patent: January 12, 2021Assignee: MD HEALTHCARE INC.Inventor: Yoon-Keun Kim
-
Patent number: 10888592Abstract: The present invention relates to pharmaceutical and food compositions for inducing satiation and prolonging satiety in subjects in need thereof. In particular, the present invention relates to a method of inducing satiation in a subject in need thereof comprising administering to the subject an effective amount of Hafnia alvei.Type: GrantFiled: April 5, 2017Date of Patent: January 12, 2021Assignees: TARGEDYS, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Serguei Fetissov, Pierre Dechelotte, Jonathan Breton, Gregory Lambert, Romain Legrand, Nicolas Lucas
-
Patent number: 10888593Abstract: Disclosed are compositions and methods that include or utilize plant growth promoting rhizobacteria (PGPR) for improving growth and health in plants and animals. The compositions and methods include or utilize a plant growth promoting rhizobacteria (PGPR) that expresses a protein associated with pectin metabolism, and a saccharide comprising pectin or a pectin-related saccharide.Type: GrantFiled: March 30, 2017Date of Patent: January 12, 2021Assignee: AUBURN UNIVERSITYInventors: Mark R. Liles, Joseph Kloepper
-
Patent number: 10888594Abstract: The present invention provides a genetically recombinant vaccinia virus effective in preventing or treating cancer. Specifically, the present invention provides a vaccinia virus comprising two polynucleotides, a polynucleotide encoding IL-7 and a polynucleotide encoding IL-12; a combination kit of two vaccinia viruses, a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12; and use of the two vaccinia viruses in combination.Type: GrantFiled: July 31, 2017Date of Patent: January 12, 2021Assignees: National University Corporation Tottori University, Astellas Pharma Inc.Inventors: Shinsuke Nakao, Tatsuya Kawase, Takafumi Nakamura
-
Patent number: 10888595Abstract: In a system and process for selectively purifying various pharmacologically-relevant components of a source plant such as cannabis, an initial step provides a low-temperature, robust essential oil/terpene capture that also dehydrates and decarboxylates the starting product—fresh raw cannabis—by means of a vacuum-assisted microwave distillation process. By doing the terpene capture under vacuum distillation temperature may be kept low. The low distillation temperature maximizes yields of thermally-sensitive components such as terpenes and cannabinoids. The system includes an oil/water separator configured to prevent leakage of ambient air into the system.Type: GrantFiled: August 4, 2017Date of Patent: January 12, 2021Inventor: Jose Rivas
-
Patent number: 10888596Abstract: The invention relates to a method of preparing cannabis extracts, including shatter, budder and wax extracts. The extraction method can provide a high quality and pure extraction product of THC from cannabis plant material, as either a shatter, wax or budder end extraction product. The extracted product is free of polar cannabis plant material, chlorophyll and residual solvents, has a high concentrate of THC, and can be used for dabbing, vaping or smoking consumption by a user. Suitable solvents for the method are gases selected from the group consisting of propane, butane or iso-butane, and the preferred solvent is propane. A key step of the method of the present invention is recovering solvent under atmospheric vacuum and, therefore, obtaining an extraction product that is purified of solvent and has no solvent.Type: GrantFiled: December 28, 2018Date of Patent: January 12, 2021Assignee: Cold Baked LLCInventor: Joshua Hindi
-
Patent number: 10888597Abstract: The present invention provides a method for treating brain stroke, including: administering to a subject in need a composition, including: an extract of a mixture, wherein the mixture includes Chuanxiong Rhizoma, Rhei Radix et Rhizoma, Angelicae Dahuricae Radix, Scutellaria baicalensis, Coptidis Rhizoma, Gardeniae Fructus, and Carica papaya.Type: GrantFiled: July 23, 2019Date of Patent: January 12, 2021Assignee: ENLIVEN BIOTECHNOLOGY CO, LTD.Inventors: Jaan-Yih Tsai, Lin-Yu Tsai, Yih-Chih Tsai
-
Patent number: 10888598Abstract: Provided herein are low salt ophthalmic pharmaceutical composition and methods of use thereof, for example, in the treatment of dry eye syndrome.Type: GrantFiled: January 23, 2018Date of Patent: January 12, 2021Assignee: ALLERGAN, INC.Inventors: Peter A. Simmons, Joseph G. Vehige
-
Patent number: 10888599Abstract: The invention relates to various compositions for improving exercise performance and/or recovery. The invention also relates to methods of using these compositions and kits including these compositions to improve exercise performance and/or recovery.Type: GrantFiled: June 13, 2016Date of Patent: January 12, 2021Assignee: Beachbody, LLCInventors: Nima Alamdari, Michael Wilson, May Lam
-
Patent number: 10888600Abstract: The present disclosure provides compositions and methods useful for treating or preventing diseases or disorders where beta amyloid accumulation or aggregation contributes to the pathology or symptomology of the disease, for example Alzheimer's disease.Type: GrantFiled: February 27, 2018Date of Patent: January 12, 2021Assignee: THE GENERAL HOSPITAL CORPORATIONInventors: Rudolph Emile Tanzi, Ana Griciuc
-
Patent number: 10888601Abstract: The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.Type: GrantFiled: April 29, 2019Date of Patent: January 12, 2021Assignee: REGENERON PHARMACEUTICALS, INC.Inventor: George D. Yancopoulos
-
Patent number: 10888602Abstract: The disclosure provides, among other things, compositions that bind to and inhibit the biological activity of soluble biomolecules, as well as pharmaceutical compositions thereof. Also provided herein are a number of applications (e.g., therapeutic applications) in which the compositions are useful.Type: GrantFiled: August 7, 2019Date of Patent: January 12, 2021Assignee: NaNotics, LLCInventor: Louis Hawthorne
-
Patent number: 10888603Abstract: The present invention provides a method of treating cancer with a combination of IL-2 (e.g., extended-PK IL-2), an integrin-binding-Fc fusion protein, and a cancer vaccine. The methods of the invention can be used to treat a broad range of cancer types.Type: GrantFiled: February 10, 2017Date of Patent: January 12, 2021Assignees: The Board of Trustees of the Leland Stanford Junior University, Massachusetts Institute of TechnologyInventors: Karl Dane Wittrup, Darrell J. Irvine, Cary Francis Opel, Kelly Dare Moynihan, Jennifer R. Cochran, Byron Hua Kwan
-
Patent number: 10888604Abstract: The present invention relates to polypeptides and analogues thereof for use in the treatment of diabetes and bone disorders. Also disclosed are pharmaceutical compositions comprising the polypeptides and analogues thereof, and methods for the treatment of diabetes and bone disorders.Type: GrantFiled: December 5, 2016Date of Patent: January 12, 2021Inventors: Victor Gault, Nigel Irwin
-
Patent number: 10888605Abstract: The present invention relates to pharmaceutical compositions of the GLP-1 peptide semaglutide comprising no more than 0.01% (w/w) phenol, their preparation, kits comprising such compositions as well as uses thereof.Type: GrantFiled: January 28, 2020Date of Patent: January 12, 2021Assignee: Novo Nordisk A/SInventors: Eva Horn Moeller, Michael Duelund Soerensen, Joakim Lundqvist
-
Patent number: 10888606Abstract: A peptide with anti-inflammatory activity is described, wherein the peptide comprises at least one amino acid sequence among SEQ ID NO: 2 to SEQ ID NO: 179, the peptide has above 80% homology of amino acid sequence with above-mentioned sequences, or the peptide is the fragment of the above-mentioned peptides. The peptides that have at least one amino acid sequence of SEQ ID NO: 2 to SEQ ID NO: 179 shows outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising those peptides can be used as anti-inflammatory pharmaceutical compositions or as cosmetic compositions, in turn, treating and preventing a variety of different types of inflammatory diseases.Type: GrantFiled: December 21, 2018Date of Patent: January 12, 2021Assignee: GEMVAX & KAEL CO., LTD.Inventors: Sang Jae Kim, Kyung Hee Kim, Kyu-Yong Lee, Seong-Ho Koh, Hyun-Hee Park, Sung Jin Huh, Woo Jin Lee, Bum Joon Kim
-
Patent number: 10888607Abstract: The present disclosure provides methods of screening, diagnosing, monitoring and/or treating acid sphingomyelinase (ASM) disorders such as Niemann-Pick disease. In particular, the methods encompass techniques for improved diagnosis and/or treatment of an ASM disorder, for example using enzyme replacement therapy.Type: GrantFiled: June 8, 2018Date of Patent: January 12, 2021Assignee: Genzyme CorporationInventors: Wei-Lien Chuang, Gerald F. Cox, X. Kate Zhang
-
Patent number: 10888608Abstract: The technology relates generally to the field of immunology and relates in part to methods for activating T cells and other cells resulting in an immune response against a target antigen. The technology also relates to costimulation of therapeutic cells that express chimeric antigen receptors that recognize target antigens using chimeric MyD88- and CD40-derived polypeptides. The technology further relates in part to therapeutic cells that express chimeric antigen receptors, wherein the chimeric antigen receptors have an endodomain that includes MyD88- and CD40-derived polypeptides, and methods for treating patients using the modified therapeutic cells.Type: GrantFiled: September 1, 2015Date of Patent: January 12, 2021Assignee: Bellicum Pharmaceuticals, Inc.Inventors: David Spencer, Aaron Edward Foster, Kevin Slawin
-
Patent number: 10888609Abstract: The present invention provides in certain embodiments compositions comprising at least one CD200 inhibitor, and methods of reversing or modulating immune suppression in a patient having a disease or disorder arising from abnormal cell growth, function or behavior, which method comprises administering to a patient in need thereof a CD200 inhibitor composition.Type: GrantFiled: November 2, 2016Date of Patent: January 12, 2021Assignee: Regents of the University of MinnesotaInventor: Michael Olin